182 related articles for article (PubMed ID: 29343029)
1. [microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor].
Ai ZD; Wu HY; Chen L
Zhonghua Yi Xue Za Zhi; 2018 Jan; 98(1):46-50. PubMed ID: 29343029
[No Abstract] [Full Text] [Related]
2. Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl.
Wu H; Yin J; Ai Z; Li G; Li Y; Chen L
J Cancer; 2019; 10(23):5671-5680. PubMed ID: 31737104
[No Abstract] [Full Text] [Related]
3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
4. [Overexpression of miR-30a Promotes Apoptosis of Leukemia K562 Cells].
Xu M; Gao WW; Luo YJ; Wang Y; Tao K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):396-402. PubMed ID: 30998144
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
7. MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.
Wang L; Wang Y; Lin J
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8789-8796. PubMed ID: 30575920
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
9. miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL.
Liang B; Song Y; Zheng W; Ma W
Med Sci Monit; 2016 Aug; 22():2761-7. PubMed ID: 27492780
[TBL] [Abstract][Full Text] [Related]
10. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
Wang W; DU Y; Lin GQ; Li NN; Sun BZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
12. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
13. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Zhang JH; He YL; Zhu R; Du W; Xiao JH
Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
[TBL] [Abstract][Full Text] [Related]
15. [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
Liu YY; You LS; Qian WB; Tong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):473-8. PubMed ID: 23086637
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.
Xishan Z; Ziying L; Jing D; Gang L
Sci Rep; 2015 Jul; 5():12460. PubMed ID: 26228085
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.
Jiang MJ; Dai JJ; Gu DN; Huang Q; Tian L
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):372-378. PubMed ID: 28986256
[TBL] [Abstract][Full Text] [Related]
19. [miR-328 Inhibits K562 Cell Proliferation by Up-regulation of C/EBPα Expression].
Cao JX; Wen F; Wang H; Liao P; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):350-5. PubMed ID: 25948184
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
